Tesamorelin

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). In some regions it has regulatory approval for specific HIV-associated indications related to excess visceral adipose tissue.

Beyond labeled indications, tesamorelin appears in broader metabolic and body- composition discussions, though such uses may not be supported to the same evidentiary or regulatory standard.

Tesamorelin binds to GHRH receptors in the pituitary, stimulating endogenous growth hormone secretion and, downstream, influencing IGF-1 and metabolic pathways. Its effects on body composition and lipid metabolism are thought to be mediated through these GH/IGF-1–related mechanisms.

The pattern and magnitude of response can vary with dose, duration, and baseline GH-axis function, as well as with comorbid conditions such as HIV infection.

In regions where tesamorelin is approved, labeled indications focus on specific HIV-associated changes in visceral adipose tissue. Use is typically guided by infectious disease and endocrine specialists.

Outside these indications, tesamorelin may be discussed in relation to general obesity, metabolic risk, or body composition. Such uses should be evaluated carefully against local regulations, available evidence, and the balance of potential risks and benefits.

Tesamorelin is named individually on the WADA Prohibited List, in the GHRH-analogue bullet of sub-section S2.2.4, "Growth hormone releasing factors," alongside CJC-1293, CJC-1295 and sermorelin. Class S2 substances are non-Specified Substances, which sets the default first-violation sanction at four years.

Approval does not create an exception — but it does open a route. Tesamorelin is the unusual case in this sub-section: unlike the research peptides listed beside it, it is an approved medicine in some jurisdictions, licensed for HIV-associated excess visceral abdominal fat. That distinction matters in one direction only. Being an approved drug does not remove a substance from the Prohibited List — somatropin, testosterone and EPO are all licensed medicines and all prohibited. What approval does provide is a documented indication against which a therapeutic use exemption can be assessed. An athlete with the labelled HIV-associated indication has a real TUE pathway; an athlete using it for general body composition or visceral fat reduction does not, because a TUE requires that no reasonable permitted alternative exists and that the treatment produce no additional performance enhancement beyond a return to normal health (USADA, therapeutic use exemptions). Applications are made in advance, to the relevant anti-doping organization, not to a prescriber — USADA asks athletes "to submit a TUE 30 days in advance of their planned use of any prohibited medication or method." Tesamorelin is described in the NIH LiverTox monograph as "a synthetic 44 amino acid polypeptide analogue of growth hormone releasing hormone (GHRH)" whose "N terminal portion of the molecule has been modified to improve its stability and pharmacokinetics in comparison to native GHRH" (LiverTox, NIH) — that modification is precisely what makes it a distinguishable target for a laboratory.

Detection. Tesamorelin is an explicit target analyte in at least three validated doping-control methods: an immunoaffinity plasma assay with a "lower limit of detection (<50 pg/mL)" (Knoop et al., Anal Bioanal Chem 2016); an in vitro metabolism study that synthesised nineteen GHRH-analogue metabolites as reference materials and reached limits "generally 1 ng/ml (WADA required performance limit) or less" (Memdouh et al., Drug Test Anal 2021); and a WADA-validated nano-LC-Orbitrap urine method reporting "LODs (≤ 0.5 ng/mL)" (Uçaktürk and Nemutlu, J Pharm Biomed Anal 2026). The same 2021 review is candid that GHRH analogues "do not appear to have been found in anti-doping samples by WADA accredited laboratories" despite intelligence indicating use — a gap the subsequent method development was designed to close, and one that stored-sample re-analysis can reach backwards into.

Reported side effects include injection-site reactions, arthralgia, peripheral edema, and changes in glucose tolerance in some individuals. Because it modulates GH and IGF-1, there is ongoing interest in long-term safety, particularly in populations with existing metabolic or cardiovascular risk.

Clinician oversight, appropriate patient selection, and regular monitoring are essential parts of safe use.

Tesamorelin is a GHRH analog with a specific clinical approval for visceral fat reduction in HIV-associated lipodystrophy.

This information is based on the FDA-approved labeling for Egrifta.

Two approved presentations exist and they are not interchangeable. EGRIFTA SV supplies a 2 mg vial reconstituted with 0.5 mL of sterile water for a single 1.4 mg daily dose; EGRIFTA WR supplies an 11.6 mg vial reconstituted weekly with 1.3 mL of bacteriostatic water to provide seven 1.28 mg daily doses. The labeling states explicitly that the two products differ in dose, vials per dose, reconstitution, and storage, and are not substitutable.

No combination product containing tesamorelin is approved. It is sometimes discussed alongside ghrelin-receptor peptides such as ipamorelin on the rationale that GHRH and ghrelin pathways are complementary, but that pairing has no trial evidence behind it and none of the data on this page describes it.

Clinical trials of tesamorelin in HIV-associated lipodystrophy have examined endpoints such as visceral fat volume, metabolic markers, and quality of life. Additional research explores broader metabolic effects and durability of response.

As evidence accumulates, questions remain about long-term outcomes, optimal patient selection, and how tesamorelin compares with other interventions. High-level educational summaries should be paired with direct review of primary data when making clinical decisions.

For deeper dives on this peptide, see:

• Tesamorelin benefits and areas of interest
• Tesamorelin side effects and safety context
• Tesamorelin dosing concepts (educational)
• Tesamorelin research and evidence overview

Is tesamorelin FDA-approved? Yes, for one indication: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Two products are currently marketed — EGRIFTA SV and EGRIFTA WR — and the label states they are not substitutable (EGRIFTA SV prescribing information, DailyMed).

How much visceral fat does it actually remove? In the pooled phase 3 analysis of 806 adults on 2 mg daily, visceral adipose tissue fell 24 ± 41 cm² versus a 2 ± 35 cm² increase on placebo at week 26 — a −15.4% treatment effect — reaching −17.5% by week 52 (J Clin Endocrinol Metab 2010; PMID 20554713).

Does the fat come back if you stop? Yes. In the 404-patient trial, participants switched from tesamorelin to placebo rapidly lost the VAT improvement they had gained over six months (J Acquir Immune Defic Syndr 2010; PMID 20101189). It is an ongoing therapy, not a course with a lasting result.

Is the dose 2 mg per day? Not any more. The 2 mg figure comes from the original trials and the discontinued first-generation product. The currently approved doses are 1.4 mg daily for EGRIFTA SV and 1.28 mg daily for EGRIFTA WR, with different vial strengths and reconstitution instructions for each.

Does it affect blood sugar? The label carries a glucose intolerance warning: 5% of treated patients developed an HbA1c of 6.5% or higher versus 1% on placebo, with a hazard ratio of 3.3 for developing diabetes. Growth hormone opposes insulin, so this is inherent to the mechanism rather than incidental.

How does it compare with sermorelin or CJC-1295? All three act on the GHRH receptor, but only tesamorelin has a randomised phase 3 programme, an FDA label, and published data on what happens after discontinuation. The difference is evidence, not concept.